Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX-D in First-line Metastatic Pancreatic Adenocarcinoma
NCT01652976Phase 2Completed
- Sponsor
- University of Florida
- Start
- Jul 2012
- Primary completion
- Feb 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in pancreatic adenocarcinoma (PDAC), sponsored by University of Florida. Primary endpoint: Progression Free Survival at 3 years. Started Jul 2012; status: completed.
02
Drugs
dasatinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01652976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01652976.